Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Total Current Liabilities (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Total Current Liabilities data on record, last reported at $19.1 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 5.28% year-over-year to $19.1 million; the TTM value through Sep 2025 reached $19.1 million, down 5.28%, while the annual FY2024 figure was $19.9 million, 148.98% up from the prior year.
  • Total Current Liabilities reached $19.1 million in Q3 2025 per RANI's latest filing, down from $20.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $20.6 million in Q2 2025 and bottomed at $2.6 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $10.9 million, with a median of $7.3 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: plummeted 50.26% in 2021, then skyrocketed 189.12% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $2.6 million in 2021, then skyrocketed by 82.39% to $4.8 million in 2022, then skyrocketed by 65.92% to $8.0 million in 2023, then surged by 148.98% to $19.9 million in 2024, then decreased by 3.76% to $19.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $19.1 million in Q3 2025, $20.6 million in Q2 2025, and $20.1 million in Q1 2025.